OVID Ovid Therapeutics
- 1.050
- +0.020+1.94%
Ovid Therapeutics News
Express News | Ovid Therapeutics Inc - Anticipates Moving Its Pipeline Forward With Multiple Milestones Expected in Second Half of 2024
Express News | Ovid Therapeutics Expands Scientific Advisory Board With Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?
Ladenburg Thalmann Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $2
ENeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $5
TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target
Ovid Therapeutics Analyst Ratings
Buy Rating Affirmed for Ovid Therapeutics Following Promising Phase 1 Results of OV888/GV101
Ovid Therapeutics' Promising Drug Safety and Biomarker Developments Garner Buy Rating
Buy Rating for Ovid Therapeutics Backed by Strong Clinical Data and Strategic Management
Express News | Ovid: Phase 2 Study for Treatment of Cerebral Cavernous Malformations Is Expected to Initiate in H2
Express News | Ovid Therapeutics Inc - No Serious Adverse Events Reported in Phase 1 Study
Express News | Ovid Therapeutics Inc - Phase 1 Study for Ov888/Gv101 Capsule Meets Its Objective
Express News | Ovid Therapeutics and Graviton Bioscience Announce Topline Data From a Phase 1 Clinical Trial Studying Ov888/Gv101 Capsule, a Potential First-in-Class Therapy for Cerebral Cavernous Malformations
Express News | Ovid Therapeutics - Believes That Its Cash Runway Will Be Sufficient to Fund Its Operations Into the First Half of 2026
Express News | Ovid Therapeutics Inc - Anticipates a One-Time Severance-Related Charge Associated With Workforce Reduction to Be Approximately $4.0 Mln
Analysis
Price Target
No Data
